Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

GRECCO-19, 2020
 
NCT04326790
RCTcolchicinestandard of careCOVID 19 hospitalizedsome concern
55/50 suggested
  • suggested 89 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
Salehzadeh, 2020
 
IRCT20200418047126N1
RCTcolchicineplaceboCOVID 19 hospitalizedsome concern
50/50 inconclusive
    Comparing two groups showed significantly different only in the duration of hospitalized (P<0.05). Although in colchicine group dyspnea was improved more rapid than the placebo group, but it was not meaningful.
    Bousquet, 2020 OBSanticoagulant, prophylactic dosecontrolCOVID 19 hospitalizedNA
    -/- suggested
    • suggested 57 % decrease in deaths
    Bousquet, 2020 OBSanticoagulant, prophylactic doseanticoagulant, curative doseCOVID 19 hospitalizedNA
    -/- inconclusive
      Bousquet, 2020 OBSanticoagulant, curative dosecontrolCOVID 19 hospitalizedNA
      -/- suggested
      • suggested 62 % decrease in deaths
      Paranjpe, 2020 OBSanticoagulantcontrolCOVID 19 hospitalizedcritical
      786/1987 no results
        the primary result seems inconclusive (no p value given, but in-hospital mortality for AC was 22.5% with a median survival of 21 days, compared to 22.8% and median survival of 14 days in control group)

        COVID-19 mild to moderate meta-analysis

        Lopes MIF, 2020
         
        RBR-8jyhxh
        RCTcolchicineplaceboCOVID-19 mild to moderatehigh
        17/18 no results

          COVID-19 severe or critically meta-analysis

          Tang, 2020 OBSanticoagulant, prophylactic dosecontrolCOVID-19 severe or criticallyserious
          99/350 inconclusive

            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).